Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.58 |
| ▸ | FNTA | P49354 | 3/20 | 0.54 |
| ▸ | FNTB | P49356 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.46 |
| ▸ | ITGAV | P06756 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226074 | 0.92 | L3MBTL1 (0.68) | L3MBTL1FFAR1FNTAFNTBKMT2A | |
| SCHEMBL11221382 | 0.84 | LMNA (0.43) | L3MBTL1FFAR1FNTAFNTBPOLB | |
| SCHEMBL2471169 | 0.83 | FNTA (0.50) | L3MBTL1FFAR1FNTAFNTBKMT2A | |
| SCHEMBL4453571 | 0.83 | FFAR1 (0.78) | L3MBTL1FFAR1FNTAFNTBKMT2A | |
| SCHEMBL8589119 | 0.83 | L3MBTL1 (0.61) | L3MBTL1FFAR1FNTAFNTBKMT2A | |
| SCHEMBL10200947 | 0.82 | GABBR2 (0.64) | L3MBTL1FFAR1FNTAFNTBKMT2A | |
| SCHEMBL9541616 | 0.81 | GABBR2 (0.61) | FNTAFNTBKMT2APOLB | |
| SCHEMBL657290 | 0.81 | GABBR2 (0.61) | FNTAFNTBKMT2APOLB | |
| SCHEMBL2471681 | 0.80 | GAA (0.56) | POLB | |
| SCHEMBL657719 | 0.80 | FNTA (0.50) | FFAR1FNTAFNTBKMT2AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149558-A1 | Benzo-fused 5-membered heterocyclic compounds, their production and use | OHKAWA SHIGENORI | 2007-06-28 | — | — | US | disclosed |
| US-7208495-B2 | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20040167171-A1 | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-26 | — | — | US | disclosed |
| EP-1411052-A1 | BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149558-A1 | Benzo-fused 5-membered heterocyclic compounds, their production and use | CBR1, DBH, PARK7 | L3MBTL1 646/4885FFAR1 2448/4885FNTA 4479/4885 |
| US-20040167171-A1 | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof | CYP8B1, PARK7, OXER1 | L3MBTL1 2384/4885FFAR1 1902/4885FNTA 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.